Oxford Nanopore Technologies plc (LON:ONT)
114.50
-0.70 (-0.61%)
Apr 8, 2026, 4:50 PM GMT
LON:ONT Revenue
In the year 2025, Oxford Nanopore Technologies had annual revenue of 223.90M GBP with 22.22% growth. Oxford Nanopore Technologies had revenue of 118.30M in the half year ending December 31, 2025, with 41.40% growth.
Revenue
223.90M
Revenue Growth
+22.22%
P/S Ratio
4.98
Revenue / Employee
167.72K
Employees
1,335
Market Cap
1.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 223.90M | 40.71M | 22.22% |
| Dec 31, 2024 | 183.19M | 13.52M | 7.97% |
| Dec 31, 2023 | 169.67M | -28.94M | -14.57% |
| Dec 31, 2022 | 198.60M | 64.94M | 48.59% |
| Dec 31, 2021 | 133.66M | 19.80M | 17.39% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genus | 672.00M |
| Oxford Biomedica | 168.74M |
| hVIVO | 54.47M |
| Bioventix | 12.54M |
| Scancell Holdings | 4.71M |
| PureTech Health | 4.66M |
| 4basebio | 1.78M |
| Ondine Biomedical | 1.18M |
Oxford Nanopore Technologies News
- 22 days ago - Oxford Nanopore and A.D.A.M. Innovations Announce International Collaboration to Accelerate Advanced Genomic Medicine in Japan - Business Wire
- 4 weeks ago - ViruSure Launches First GMP-Validated Viral Safety Test Based on Oxford Nanopore Sequencing - Business Wire
- 3 months ago - Oxford Nanopore Receives Regulatory Approval for its First Diagnostic Device in the UK and Europe - Business Wire
- 6 months ago - Oxford Nanopore Announces PromethION Plus Flow Cell and Human Genetics Updates at ASHG 2025 - Business Wire
- 8 months ago - ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology - Business Wire
- 1 year ago - Breakthrough algorithm enables partially phased, near telomere-to-telomere assembly using standard Oxford Nanopore Simplex reads - Business Wire
- 1 year ago - Oxford Nanopore Expands Compatible Products Programme and Strengthens Multi-Omics Ecosystem - Business Wire
- 1 year ago - Oxford Nanopore and UK Biobank to create world's first epigenetic dataset targeting the causes of cancer, dementia, complex disease - Business Wire